Retirement Planning Co of New England Inc. Acquires 13,684 Shares of Danaher Corporation $DHR

Retirement Planning Co of New England Inc. acquired a new position in shares of Danaher Corporation (NYSE:DHR) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 13,684 shares of the conglomerate’s stock, valued at approximately $3,032,000. Danaher comprises approximately 1.1% of Retirement Planning Co of New England Inc.’s holdings, making the stock its 19th biggest position.

A number of other institutional investors have also recently bought and sold shares of the company. Main Street Group LTD acquired a new position in Danaher in the 1st quarter worth about $25,000. N.E.W. Advisory Services LLC purchased a new stake in shares of Danaher during the 2nd quarter worth about $25,000. Marquette Asset Management LLC raised its stake in shares of Danaher by 192.1% during the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 73 shares in the last quarter. Evolution Wealth Management Inc. lifted its holdings in shares of Danaher by 208.0% during the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after buying an additional 104 shares during the last quarter. Finally, Field & Main Bank acquired a new stake in shares of Danaher during the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Trading Up 3.0%

Danaher stock opened at $231.52 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company’s fifty day moving average price is $213.55 and its two-hundred day moving average price is $195.74.

Danaher (NYSE:DHR) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the company earned $0.77 earnings per share. The business’s revenue was up 5.5% compared to the same quarter last year. On average, analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Royal Bank Of Canada raised their price objective on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. The Goldman Sachs Group raised their price objective on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Finally, TD Cowen boosted their target price on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.